Literature DB >> 21556033

Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels.

Thomas J Montine1.   

Abstract

Biomarker development is important to the therapeutic imperative for neurodegenerative diseases, as biomarkers hold transformative promise for the design and conduct of clinical trials and, ultimately, for medical management of these diseases. Some of this promise is now being realized in Alzheimer disease, and progress in Parkinson disease is accelerating.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21556033      PMCID： PMC4043344          DOI： 10.1038/nrneurol.2011.66

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  8 in total

Review 1.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Authors:  John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.

Authors:  Ignacio F Mata; Min Shi; Pinky Agarwal; Kathryn A Chung; Karen L Edwards; Stewart A Factor; Douglas R Galasko; Carmen Ginghina; Alida Griffith; Donald S Higgins; Denise M Kay; Hojoong Kim; James B Leverenz; Joseph F Quinn; John W Roberts; Ali Samii; Katherine W Snapinn; Debby W Tsuang; Dora Yearout; Jing Zhang; Haydeh Payami; Cyrus P Zabetian
Journal:  Arch Neurol       Date:  2010-11

3.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

4.  Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease.

Authors:  Ivana Devic; Hyejin Hwang; John Scott Edgar; Kenneth Izutsu; Richard Presland; Catherine Pan; David R Goodlett; Yu Wang; Jeff Armaly; Vitor Tumas; Cyrus P Zabetian; James B Leverenz; Min Shi; Jing Zhang
Journal:  Brain       Date:  2011-02-24       Impact factor: 13.501

5.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Authors:  Brit Mollenhauer; Joseph J Locascio; Walter Schulz-Schaeffer; Friederike Sixel-Döring; Claudia Trenkwalder; Michael G Schlossmacher
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

6.  CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

Authors:  Thomas J Montine; Min Shi; Joseph F Quinn; Elaine R Peskind; Suzanne Craft; Carmen Ginghina; Kathryn A Chung; Hojoong Kim; Douglas R Galasko; Joseph Jankovic; Cyrus P Zabetian; James B Leverenz; Jing Zhang
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

7.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression.

Authors:  Min Shi; Joshua Bradner; Aneeka M Hancock; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Un Jung Kang; Kevin C Cain; Yu Wang; Jan Aasly; David Goldstein; Jing Zhang
Journal:  Ann Neurol       Date:  2011-03-11       Impact factor: 10.422

Review 8.  Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia.

Authors:  Joshua A Sonnen; Kathleen S Montine; Joseph F Quinn; John C S Breitner; Thomas J Montine
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472
  8 in total
  1 in total

1.  Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.

Authors:  Michael Bidinosti; Derya R Shimshek; Brit Mollenhauer; David Marcellin; Tatjana Schweizer; Gregor P Lotz; Michael G Schlossmacher; Andreas Weiss
Journal:  J Biol Chem       Date:  2012-07-27       Impact factor: 5.157
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.